-+ 0.00%
-+ 0.00%
-+ 0.00%
Missed Exelixis's Run? What Holders Had To Believe
Share
Listen to the news

If you had bought Exelixis on 19 November 2025 and simply sat tight, the outcome would look very different today. Holding Exelixis over the past year would have returned 57.6%, including dividends. That headline invites a harder question. At the time, you were staring at an oncology specialist tied closely to cabozantinib, rising 340B pressure, and an unproven zanzalintinib franchise. If you were weighing that decision then, how much conviction could you really have in Exelixis becoming more than a single-drug story?

Exelixis has already moved. Pinpoint other ways to investigate the theme among 36 healthcare AI stocks.

The Two Exelixis Stories Investors Were Arguing About

The shares cost US$42.14 at the start of the period. Anyone looking at Exelixis then had to choose between a growth script powered by oncology demand and a much more cautious pricing and regulation story.

On the bullish side, the optimistic narrative saw a Fair Value of US$60, a price implied by expectations that a broader oncology portfolio could justify it. Supporters leaned on assumptions that zanzalintinib might eventually eclipse the cabozantinib franchise in high value, lower competition indications.

The bearish narrative pointed to a Fair Value of US$36, again an implied price based on its own set of forecasts. This camp focused on the risk that rising 340B volume near 24% and tighter drug price scrutiny could compress margins even if cabozantinib demand held up.

NasdaqGS:EXEL 1-Year Stock Price Chart
NasdaqGS:EXEL 1-Year Stock Price Chart

What The Results Changed In The Exelixis Debate

Exelixis kept cabozantinib at the center of the story, with Q3 2026 revenue of US$658.7 million and net income of US$218.1 million, which supported the optimistic script that the core franchise could still pull higher profit and a slightly stronger 33.1% margin. The extension of the FDA review for zanzalintinib to March 2027 gave the cautious case fresh support. Overall, the evidence cut both ways.

The real lesson is where to point your flashlight. When a single product carries most of the load, track both revenue mix and net margin alongside every big regulatory date. That is how you test whether a diversification story at another biotech is actually progressing or just being talked about.

What Exelixis Buyers Are Assuming After The Run

Exelixis now trades at US$65.83. The bearish analyst Narrative on Simply Wall St views its Fair Value as below that quote, framing today’s price as already baking in meaningful success from cabozantinib cash generation and a broader oncology pipeline.

The same Narrative argues that for this level to hold, investors must judge that cabozantinib strength, disciplined R&D and the zanzalintinib program together can support a durable multi asset oncology model without leaving earnings overly exposed to execution slips.

"The main requirement is that Exelixis successfully converts its cabozantinib cash flows and broad zanzalintinib trial program into a durable multi-franchise oncology business, while keeping R&D spending disciplined and using AI and cost controls to support free cash flow."

The price and this Narrative do not agree. → Uncover what this Narrative says Exelixis is actually worth

How Could You Get There Earlier?

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

  • Company 1 - 27% below our estimate - equips AI data centres with liquid cooling and power systems that shrink water consumption.
  • Company 2 - 47% below our estimate - scales an asset-light hotel network while layering on a fast-growing branded retail platform.
  • Company 3 - 37% below our estimate - expands an online used car marketplace built around integrated logistics, reconditioning and customer financing.

That is three of the list. See every one of the 35 undervalued companies on it →

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending